- Home
- MNR vs IRON Comparison
MNR vs IRON Comparison
Compare MNR & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNR
- IRON
- Stock Information
- Founded
- MNR 2017
- IRON 2017
- Country
- MNR United States
- IRON United States
- Employees
- MNR 444
- IRON N/A
- Industry
- MNR
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- MNR
- IRON Health Care
- Exchange
- MNR Nasdaq
- IRON Nasdaq
- Market Cap
- MNR 1.8B
- IRON 1.9B
- IPO Year
- MNR 2023
- IRON N/A
- Fundamental
- Price
- MNR $17.83
- IRON $57.86
- Analyst Decision
- MNR Strong Buy
- IRON Strong Buy
- Analyst Count
- MNR 3
- IRON 10
- Target Price
- MNR $25.00
- IRON $73.70
- AVG Volume (30 Days)
- MNR 166.0K
- IRON 263.4K
- Earning Date
- MNR 11-12-2024
- IRON 03-20-2025
- Dividend Yield
- MNR 17.94%
- IRON N/A
- EPS Growth
- MNR N/A
- IRON N/A
- EPS
- MNR N/A
- IRON N/A
- Revenue
- MNR $873,766,000.00
- IRON N/A
- Revenue This Year
- MNR $50.49
- IRON N/A
- Revenue Next Year
- MNR $0.10
- IRON N/A
- P/E Ratio
- MNR N/A
- IRON N/A
- Revenue Growth
- MNR 21.20
- IRON N/A
- 52 Week Low
- MNR $14.46
- IRON $25.60
- 52 Week High
- MNR $21.19
- IRON $77.60
- Technical
- Relative Strength Index (RSI)
- MNR 74.80
- IRON 42.10
- Support Level
- MNR $16.86
- IRON $58.15
- Resistance Level
- MNR $17.98
- IRON $62.02
- Average True Range (ATR)
- MNR 0.46
- IRON 3.01
- MACD
- MNR 0.06
- IRON -0.42
- Stochastic Oscillator
- MNR 84.87
- IRON 27.52
About MNR Mach Natural Resources LP
Mach Natural Resources LP is an independent upstream oil and gas company focused on the acquisition, development and production of oil, natural gas and NGL reserves in the Anadarko Basin region of Western Oklahoma, Southern Kansas and the panhandle of Texas.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. The company is building a portfolio of inventive therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease. The Company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis.